Osiris Therapeutics clinical trials
Acquired by Smith & Nephew, Inc., Apr 17, 2019 · source ↗
The registry lists 7 studies whose lead sponsor is Osiris Therapeutics. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 12, 2022.
Before and after it joined Smith & Nephew, Inc.
- First submitted before Osiris Therapeutics became part of Smith & Nephew, Inc.
- 7
- First submitted after Osiris Therapeutics became part of Smith & Nephew, Inc.
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Osiris Therapeutics7 studies
Something wrong with this grouping? Tell us on the Smith & Nephew, Inc. page.
Studies
Recruiting first, then most recently updated. Showing 7 of 7. All Smith & Nephew, Inc. studies →
- Study to Evaluate Safety and Efficacy of GrafixPL for the Treatment of Venous Leg UlcersCompletedNCT03629236Not applicable
Sponsor listed in the registry: Osiris Therapeutics · First submitted before Osiris Therapeutics became part of Smith & Nephew, Inc.
- Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot UlcersTerminatedNCT02571738Phase 3
Sponsor listed in the registry: Osiris Therapeutics · First submitted before Osiris Therapeutics became part of Smith & Nephew, Inc.
- GrafixPRIME® for the Treatment of Chronic Diabetic Foot UlcersCompletedNCT02675855Phase 4
Sponsor listed in the registry: Osiris Therapeutics · First submitted before Osiris Therapeutics became part of Smith & Nephew, Inc.
- TruSkin®: Study for the Treatment of Chronic Diabetic Foot UlcersTerminatedNCT02936115Phase 4
Sponsor listed in the registry: Osiris Therapeutics · First submitted before Osiris Therapeutics became part of Smith & Nephew, Inc.
- TruSkin®: Study for Treatment of Chronic Venous Leg UlcersTerminatedNCT02936128Phase 4
Sponsor listed in the registry: Osiris Therapeutics · First submitted before Osiris Therapeutics became part of Smith & Nephew, Inc.
- GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot WoundsCompletedNCT02260609Phase 4
Sponsor listed in the registry: Osiris Therapeutics · First submitted before Osiris Therapeutics became part of Smith & Nephew, Inc.
- Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot UlcersCompletedNCT01596920Phase 4
Sponsor listed in the registry: Osiris Therapeutics · First submitted before Osiris Therapeutics became part of Smith & Nephew, Inc.